#Japan #Tokyo #newborn screening #Sekisui Medical #Himawari Association

Sekisui Chemical Group and Himawari Association Collaborate

Sekisui Chemical Co., Ltd., led by President Ikusuke Shimizu, has joined forces with the non-profit organization Himawari Association, headed by Seiko Noda, to enhance awareness of expanded newborn screening tests. This initiative aims to clarify the significance of these screenings in preventing severe health issues for newborns.

The expanded newborn screening test extends beyond traditional screenings, encompassing voluntary checks for rare congenital diseases. Recognizing these conditions early can lead to timely intervention and a variety of treatment options. Despite this, the current landscape presents challenges, as the content of tests, access opportunities, and cost-sharing differ across municipalities, leading to a complex scenario where adequate information is not readily available.

In response to this, Sekisui Medical Co., a subsidiary responsible for medical ventures under Sekisui Chemical, is committed to ensuring parents receive accurate and comprehensible information about expanded newborn screenings. The partnership with Himawari Association is focused on promoting understanding through various efforts, including:

• - Dissemination of information regarding expanded newborn screening tests
• - Creation of educational content targeted at parents and wider audiences
• - Hosting seminars and events aimed at raising awareness
• - Collaborating with relevant agencies and healthcare professionals for outreach efforts

The Importance of Expanded Newborn Screening

Expanded newborn screening is pivotal as it systematically tests for conditions that could significantly impact a baby's health. In Japan, newborns typically undergo a mass screening around the 4th to 6th day post-birth, involving a small blood sample taken from their heel. Currently, approximately 20 conditions are included in this essential check, enabling early detection, which is critical for timely treatment.

Recent advancements in the medical field have led to develop treatment methods and drugs for these rare diseases, enhancing the potential for improved patient outcomes when identified early. This evolving landscape has catalyzed a broader adoption of expanded newborn screening initiatives, ultimately aiming to safeguard the health of future generations.

About Himawari Association

The Himawari Association is dedicated to creating a society in which pregnant and parenting individuals can live confidently and securely. Their initiatives have included distributing maternity stickers through local maternal and child health services, promoting maternity markers at highway service areas, and providing essential information related to childbirth and child-rearing. The organization has also prioritized collaborations with administrative and medical institutions to improve supportive environments. Moving forward, they aim to expand their contributions to social betterment through various projects focused on supporting families.

Looking Ahead

As part of this collaboration, Sekisui Medical is committed to addressing disparities in information and cost associated with expanded newborn screenings. Their goal is to establish a society where all newborns can access these vital screenings at no cost, regardless of where they are born. The initiative strives to pave the way for a healthier future for infants across the nation.

The partnership between Sekisui Chemical and the Himawari Association represents a significant step towards minimizing the risks of rare diseases in newborns and ensuring that every baby receives optimal care from the start. Together, they are dedicated to fostering a supportive and informed community that prioritizes the health of the youngest members of society.